| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over |
|
Medicine details |
|
| Medicine name | crovalimab |
| Formulation | 340 mg solution for injection/infusion |
| Reference number | 5180 |
| Indication | As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): • In patients with haemolysis with clinical symptom(s) indicative of high disease activity. • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months |
| Company | Roche |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/09/2024 |
| NICE guidance | TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over |